chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 65.0
Sex: F
Vaccine: VARZOS
Symptoms: Pneumonia, Vaccination complication
Clinical narrative: Information has been received on 15-FEB-2019 regarding a case in litigation concerning a 66 year old female patient. The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient was prescribed ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In December 2015, the patient was administered the ZOSTAVAX vaccine (lot# and route not specified) by a health provider. In 2016, the patient was treated by a physician for pneumonia as a result of vaccination with ZOSTAVAX. The outcome was not provided. Upon internal review pneumonia was considered a medically significant event. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received on 15-FEB-2019 regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient was prescribed ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 15-OCT-2013, the patient was administered the ZOSTAVAX vaccine (lot# and route not specified) by a healthcare provider. On an unspecified date, the patient was treated by a healthcare provider for shingles as a result of vaccination with ZOSTAVAX. The outcome was not provided. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information was received on 15-FEB-2019 from a lawyer regarding a case in litigation regarding a female patient, history not specified. On or about 05-NOV-2015, at age 66, the patient was prescribed and administered ZOSTAVAX at a pharmacy for the prevention of shingles and zoster related conditions. On an unspecified date the patient was treated by a physician at an urgent care for the following injuries resulting from ZOSTAVAX use: shingles. The outcome of shingles was not specified.   Additional information has been requested.
Age: 69.0
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information was received on 15-FEB-2019 from a lawyer regarding a case in litigation regarding a male patient, history not specified. On or about 24-SEP-2012, at age 69, the patient was prescribed and administered ZOSTAVAX at a pharmacy by a pharmacist for the prevention of shingles and zoster related conditions. On an unspecified date the patient was treated by a physician at an urgent care for the following injuries resulting from ZOSTAVAX use: shingles. The outcome of shingles was not specified. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster, Medical induction of coma, Pneumonia
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age.No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 01-FEB-2013, the patient was administered the ZOSTAVAX by a health care provider (lot number, dosage and route of administration not provided). On an unknown date, the patient was treated by a by a health care provider at a hospital for the following injuries resulting from her use of ZOSTAVAX: shingles, pneumonia and a medically induced coma. The patient claims damages as a result of: injury to herself, and economic losses. The outcome of the events is unknown. Upon internal review, pneumonia, and medically induced coma were determined medically significant. Additional information has been requested.
Age: 77.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 04-MAY-2015, the patient was administered the ZOSTAVAX by a health care provider (lot number, dosage and route of administration not provided). On an unknown date, the patient was treated by a by a health care provider for the following injury resulting from her use of ZOSTAVAX: shingles. The patient claims damages as a result of: injury to herself, loss of consortium, loss of services, and economic losses. The outcome of the shingles is unknown. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2007, the patient was administered the ZOSTAVAX by a health care provider (lot number, dosage and route of administration not provided). On an unknown date, the patient was treated by a by a health care provider for the following injury resulting from her use of ZOSTAVAX: shingles. The patient claims damages as a result of: injury to herself, loss of consortium, loss of services, and economic losses. The outcome of the shingles is unknown. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received on 15-FEB-2019 regarding a case in litigation from a lawyer concerning a 79 year old male patient There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2013, the patient was administered the ZOSTAVAX (lot number, expiration, dose and route unknown) by a healthcare provider. On or about 20-FEB-2017, the patient was treated by a healthcare provider for the following injuries resulting from the patient's ZOSTAVAX use: shingles. The patient claims damages as a result of injury to self, loss of services and economic losses. The outcome of the event is unknown. The causality of the event is related. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received on 15-FEB-2019 regarding a case in litigation from a lawyer concerning an approximately 69 year old female patient There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2010, the patient was administered the ZOSTAVAX (lot number, expiration, dose and route unknown) by a healthcare provider at a clinic. In 2016, the patient was treated by a physician at a clinic for the following injuries resulting from the patient's ZOSTAVAX use: shingles. The patient claims damages as a result of injury to self, loss of services and economic losses. The outcome of the event is unknown. The causality of the event is related. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster, Post herpetic neuralgia
Clinical narrative: Information has been received on 15-FEB-2019 regarding a case in litigation from a lawyer concerning an approximately 57 year old female patient There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 07-JAN-2010, the patient was administered the ZOSTAVAX (lot number, expiration, dose and route unknown) by a healthcare provider at a clinic. On or about 12-NOV-2014, the patient was treated by an advance practice registered nurse physician at a health system for the following injuries resulting from the patient's ZOSTAVAX use: shingles and post-herpetic neuralgia. The patient claims damages as a result of injury to self, loss of services and economic losses. The outcome of the event is unknown. The causality of the event is related. Additional information has been requested.
Age: 66.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received on 15-FEB-2019 regarding a case in litigation from a lawyer concerning female patient of unknown age. There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In March 2017, the patient was administered the ZOSTAVAX (lot number, expiration, dose and route unknown) by a physician at a community health center. On an unknown date, the patient was treated by a physician at a hospital for the following injuries resulting from the patient's ZOSTAVAX use: shingles. The patient claims damages as a result of injury to self and economic losses. The outcome of the event is unknown. The causality of the event is related. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received on 15-FEB-2019 regarding a case in litigation from a lawyer concerning an approximately 52 year old female patient. There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2016, the patient was administered the ZOSTAVAX (lot number, expiration, dose and route unknown) by a pharmacist at a pharmacy. Later in 2016, the patient was treated by a physician at a physician's office for the following injuries resulting from the patient's ZOSTAVAX use: shingles. The patient claims damages as a result of injury to self, loss of services and economic losses. The outcome of the event is unknown. The causality of the event is related. Additional information has been requested.
Age: 71.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information was received on 15-FEB-2019 by a lawyer regarding a case in litigation, concerning a female patient, history not provided. In 2009 at age 71 the patient was prescribed and administered ZOSTAVAX by a health care provider at a medical center. On an unknown date the patient was treated by a health care provider at a medical center for shingles. Outcome was not provided. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information was received on 15-FEB-2019 by a lawyer regarding a case in litigation, concerning a male patient, history not provided. On 07-MAR-2017 the patient was prescribed and administered ZOSTAVAX by a health care provider at a medical office. On 17-MAR-2017 the patient was treated by a health care provider at a hospital. Outcome was not provided. Additional information has been requested.
Age: 60.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster, Ophthalmic herpes zoster, Vaccination complication
Clinical narrative: Information has been received on 15-FEB-2019 from a lawyer regarding a case in litigation concerning a 61 year old female patient. The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient was prescribed the ZOSTAVAX vaccine by a healthcare provider for the long-term prevention of shingles and zoster-related conditions.  On or about 01-MAR-2017, the patient was administered the ZOSTAVAX (lot# and route unknown) vaccine by a healthcare provider. On or about 27-MAR-2017 the patient was treated by two physicians for shingles and opthalmicus OD as a result of vaccination with ZOSTAVAX. The outcome of the events was unknown. Upon internal review herpes zoster opthalmicus was considered medically significant. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Death, Herpes zoster
Clinical narrative: Information has been received on 15-FEB-2019 from a lawyer regarding a case in litigation concerning a 75 year old female patient. The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient was prescribed the ZOSTAVAX vaccine by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2014 the patient was administered the ZOSTAVAX vaccine by healthcare provider (lot# and route unknown). In March 2017, the patient was treated by a physician for shingles as a result of vaccination with ZOSTAVAX.  On 17-APR-2018 the patient died. The cause of death was not provided. It is unknown if an autopsy was performed. The patient claims damages as a result of: injury to themselves, injury to the person represented; wrongful death; survivorship action, loss of services; economic losses. Upon internal review death was considered medically significant. Additional information has been requested.; Reported Cause(s) of Death: died.
Age: 71.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received on 15-FEB-2019 from a lawyer regarding a case in litigation concerning a 75 year old female patient. The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient was prescribed the ZOSTAVAX vaccine by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In January 2015 the patient was administered the ZOSTAVAX vaccine by a healthcare professional. In March 2017, the patient was treated by a nurse practitioner for shingles as a result of vaccination with ZOSTAVAX. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received on 15-FEB-2019 from a lawyer regarding a case in litigation concerning a 69 year old male patient. The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient was prescribed the ZOSTAVAX vaccine by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 02-JUL-2015 the patient was administered the ZOSTAVAX vaccine by a healthcare provider. On or about 31-MAY-2017, the patient was treated by a physician for shingles as a result of vaccination with ZOSTAVAX. Additional information has been requested.
Age: 52.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information was received on 15-FEB-2019 by a lawyer regarding a case in litigation, concerning a female patient, history not provided. In FEB-2016 at age 52, the patient was prescribed and administered ZOSTAVAX by a pharmacist at a pharmacy. In Mar-2016 the patient was treated by a physician at a medical office for shingles. Outcome was not provided. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning an approximately 73 year old female. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2015, the patient was administered the ZOSTAVAX by a pharmacist (lot number, dosage and route of administration not provided). On or about 03-MAR-2017, the patient was treated by a healthcare provider at a hospital for the following injury resulting from her use of ZOSTAVAX: shingles. The patient claims damages as a result of: injury to herself, and economic losses. The outcome of the shingles is unknown. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Ophthalmic herpes zoster, Vaccination complication
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning an approximately 60 year old female. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2011, the patient was administered the ZOSTAVAX by a health care provider (lot number, dosage and route of administration not provided). On an unknown date in 2012, the patient was treated by a health care provider for the following injury resulting from her use of ZOSTAVAX: ocular shingles. The patient claims damages as a result of: injury to herself, and economic losses. The outcome of the ocular shingles is unknown. Upon internal review, ocular shingles was determined to be medically significant. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning an approximately 69 year old male. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2013, the patient was administered the ZOSTAVAX by a health care provider (lot number, dosage and route of administration not provided). In an unknown date in 2017, the patient was treated by a healthcare provider for the following injury resulting from his use of ZOSTAVAX: shingles. The patient claims damages as a result of: injury to himself, and economic losses. The outcome of the shingles is unknown. Additional information has been requested.
Age: 79.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning an approximately 79 year old female. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2009, the patient was administered the ZOSTAVAX by a health care provider (lot number, dosage and route of administration not provided). On an unknown date in 2015, the patient was treated by a health care provider for the following injury resulting from her use of ZOSTAVAX: shingles. The patient claims damages as a result of: injury to herself, loss of consortium, loss of services, and economic losses. The outcome of the shingles is unknown. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning an approximately 64 year old male. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 04-JAN-2017, the patient was administered the ZOSTAVAX by a health care provider (lot number, dosage and route of administration not provided). On or about 17-JAN-2017, the patient was treated by a healthcare provider for the following injury resulting from his use of ZOSTAVAX: herpes zoster. The patient claims damages as a result of: injury to himself, loss of consortium, loss of services, and economic losses. The outcome of the herpes zoster is unknown. Additional information has been requested.
Age: 85.0
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning an approximately 85 year old male. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On and unknown date in 2015, the patient was administered the ZOSTAVAX by a health care provider (lot number, dosage and route of administration not provided). In March 2017, the patient was treated by a health care provider for the following injury resulting from his use of ZOSTAVAX: shingles. The patient claims damages as a result of: injury to himself, loss of consortium, loss of services, and economic losses. The outcome of the shingles is unknown. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2012, the patient was administered the ZOSTAVAX by a health care provider (lot number, dosage and route of administration not provided). On an unknown date, the patient was treated by a health care provider for the following injury resulting from his use of ZOSTAVAX: shingles. The patient claims damages as a result of: injury to himself, loss of consortium, loss of services, and economic losses. The outcome of the shingles is unknown. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a 69 year old female. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On an unknown date in 2011, the patient was administered the ZOSTAVAX by a health care provider (lot number, dosage and route of administration not provided). On or about 02-MAR-2017, the patient was treated by a health care provider for the following injury resulting from her use of ZOSTAVAX: shingles. The patient claims damages as a result of: injury to herself, and economic losses. The outcome of the shingles is unknown. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a 64 year old male. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 01-JAN-2011, the patient was administered the ZOSTAVAX by a health care provider (lot number, dosage and route of administration not provided). On or about 01-MAR-2017, the patient was treated by a healthcare provider for the following injury resulting from his use of ZOSTAVAX: shingles. The patient claims damages as a result of: injury to himself, loss of consortium, loss of services, and economic losses. The outcome of the shingles is unknown. Additional information has been requested.
Age: 68.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a 73 year old female. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 07-NOV-2009, the patient was administered the ZOSTAVAX by a health care provider (lot number, dosage and route of administration not provided). On or about 23-FEB-2015, the patient was treated by a health care provider for the following injury resulting from her use of ZOSTAVAX: shingles. The patient claims damages as a result of: injury to herself, loss of consortium, loss of services, and economic losses. The outcome of the shingles is unknown. Additional information has been requested.
Age: 63.0
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received regarding a case in litigation from a lawyer, a 63 year old male patient, and his spouse. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 13-NOV-2015, the patient was administered the ZOSTAVAX (lot number, dosage and route of administration not provided) by a pharmacist at a pharmacy. On or about 04-MAY-2016, the patient was treated by a physician for the following injury resulting from his use of ZOSTAVAX: Shingles. The outcome of the shingles is unknown. The patient claims damages as a result of: injury to themselves, loss of consortium, loss of services, and economic losses. Additional information has been requested.
Age: 71.0
Sex: M
Vaccine: VARZOS
Symptoms: Death, Herpes zoster
Clinical narrative: Information has been received regarding a case in litigation from a lawyer and the spouse of a 71 year old deceased male patient. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider at a hospital for the long-term prevention of shingles and zoster-related conditions. On or about 13-DEC-2016, the patient was administered the ZOSTAVAX (lot number, dosage and route of administration not provided) by a healthcare provider at a hospital. On or about 03-JAN-2017, the patient was treated by a physician at the hospital for the following injury resulting from his use of ZOSTAVAX: Shingles. The outcome of the shingles was unknown. The patient died on 11-DEC-2017. The cause of death was not reported. It is unknown if an autopsy was performed. There are claimed damages as a result of: injury to themselves, injury to the person represented, wrongful death, survivorship action, loss of consortium, loss of services, and economic losses. Upon internal review, death was determined to be medically significant. Additional information has been requested.; Reported Cause(s) of Death: Death.
Age: 72.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received regarding a case in litigation from a lawyer, an approximately 74 year old female patient, and her spouse. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On an unknown date in 2015, at approximately 72 years of age, the patient was administered the ZOSTAVAX (lot number, dosage and route of administration not provided) by a pharmacist at a pharmacy. On an unknown date in 2017, the patient was treated by a healthcare provider for the following injury resulting from her use of ZOSTAVAX: Shingles. The outcome of the shingles is unknown. The patient claims damages as a result of: injury to themselves, loss of consortium, loss of services, and economic losses. Additional information has been requested.
Age: 72.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning an approximately 83 year old female patient. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On an unknown date in 2006, at approximately 72 years of age, the patient was administered the ZOSTAVAX (lot number, dosage and route of administration not provided) by a physician. On an unknown date in 2017, the patient was treated by the physician for the following injury resulting from her ZOSTAVAX use: Shingles. The outcome of the shingles is unknown. The patient claims damages as a result of: injury to herself and economic losses. Additional information has been requested.
Age: 73.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received regarding a case in litigation from a lawyer, a 74 year old female patient, and her spouse. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 17-OCT-2013, the patient was administered the ZOSTAVAX (lot number, dosage and route of administration not provided) by a pharmacist at a pharmacy. On or about 27-JUL-2015, the patient was treated by a physician's assistant for the following injury resulting from her ZOSTAVAX use: Herpes zoster. The outcome of the herpes zoster is unknown. The patient claims damages as a result of: injury to themselves, loss of consortium, loss of services, and economic losses. Additional information has been requested.
Age: 80.0
Sex: U
Vaccine: VARZOS
Symptoms: Death, Herpes zoster
Clinical narrative: Information has been received regarding a case in litigation from a lawyer and an estate representative of an 82 year-old deceased patient of unknown gender. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX vaccine by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2015, at approximately 80 years of age, the patient was administered the ZOSTAVAX by a pharmacist at a pharmacy (lot number, dosage and route of administration not provided). On an unknown date, the patient was treated by a physician at a family practice medical office for the following injury resulting from the ZOSTAVAX use: Shingles. The outcome of the shingles was unknown. It was also claimed that the patient died on 30-MAR-2018 at age 82 years old. Cause of death not provided. The patient claims damages as a result of: injury to themselves, wrongful death, survivorship action, and economic losses. Upon internal review, Death was determined to be a medically significant event. Additional information has been requested.; Reported Cause(s) of Death: Death.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received on 15-FEB-2019 regarding a case in litigation from a lawyer concerning an approximately 77 year old female patient. There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 14-OCT-2011, the patient was administered the ZOSTAVAX (lot number, expiration, dose and route unknown) by a pharmacist at a pharmacy. In 2017, the patient was treated by a physician for the following injuries resulting from the patient's ZOSTAVAX use: shingles. The patient claims damages as a result of injury to self, loss of services and economic losses. The outcome of the event is unknown. The causality of the event is related. Additional information has been requested.
Age: 71.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received on 15-FEB-2019 regarding a case in litigation from a lawyer concerning an approximately 71 year old female patient. There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2016, the patient was administered the ZOSTAVAX (lot number, expiration, dose and route unknown) by a pharmacist at a pharmacy. In 2017, the patient was treated by a healthcare provider at an urgent care for the following injuries resulting from the patient's ZOSTAVAX use: shingles. The patient claims damages as a result of injury to self and economic losses. The outcome of the event is unknown. The causality of the event is related. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received on 15-FEB-2019 regarding a case in litigation from a lawyer concerning an 80 year old male patient. There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 01-JAN-2007, the patient was administered the ZOSTAVAX (lot number, expiration, dose and route unknown) by a healthcare provider. On or about 01-MAR-2017, the patient was treated by a physician for the following injuries resulting from the patient's ZOSTAVAX use: shingles. The patient claims damages as a result of injury to self and economic losses. The outcome of the event is unknown. The causality of the event is related. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received on 15-FEB-2019 regarding a case in litigation from a lawyer concerning female patient of unknown age. There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2012, the patient was administered the ZOSTAVAX (lot number, expiration, dose and route unknown) by a pharmacist at a pharmacy. On an unknown date, the patient was treated by a healthcare provider for the following injuries resulting from the patient's ZOSTAVAX use: shingles. The patient claims damages as a result of injury to self and economic losses. The outcome of the event is unknown. The causality of the event is related. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received on 15-FEB-2019 regarding a case in litigation from a lawyer concerning a 74 year old male patient of unknown age. There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2013, the patient was administered the ZOSTAVAX (lot number, expiration, dose and route unknown) by a pharmacist at a pharmacy. On or about 09-MAR-2017, the patient was treated by a physician at a physician's office for the following injuries resulting from the patient's ZOSTAVAX use: herpes zoster. The patient claims damages as a result of injury to self and economic losses. The outcome of the event is unknown. The causality of the event is related. Additional information has been requested.
Age: 75.0
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received on 15-FEB-2019 regarding a case in litigation from a lawyer concerning an approximately 77 year old male patient of unknown age. There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 25-JAN-2016, the patient was administered the ZOSTAVAX (lot number, expiration, dose and route unknown) by a healthcare provider at a physician's office. In 2017, the patient was treated by a healthcare provider for the following injuries resulting from the patient's ZOSTAVAX use: shingles. The patient claims damages as a result of injury to self, loss of services and economic losses. The outcome of the event is unknown. The causality of the event is related. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received on 15-FEB-2019 regarding a case in litigation from a lawyer concerning an approximately 68 year old female patient of unknown age. There was no information provided regarding the patient's concurrent conditions, medical history or concomitant medications. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2008, the patient was administered the ZOSTAVAX (lot number, expiration, dose and route unknown) by a healthcare provider at a community health care. In 2015, the patient was treated by a healthcare provider at a medical center for the following injuries resulting from the patient's ZOSTAVAX use: shingles. The patient claims damages as a result of injury to self and economic losses. The outcome of the event is unknown. The causality of the event is related. Additional information has been requested.
Age: 64.0
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received regarding a case in litigation from a lawyer, a male patient of unknown age, and his spouse. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 22-DEC-2008, at age 64, the patient was administered the ZOSTAVAX (lot number, dosage and route of administration not provided) by a healthcare provider. On an unknown date, the patient was treated for the following injury resulting from his use of ZOSTAVAX: Shingles. The outcome of the shingles is unknown. The patient claims damages as a result of: injury to themselves, loss of consortium, loss of services, and economic losses. Additional information has been requested.
Sex: M
Vaccine: PPV
Symptoms: Inappropriate schedule of product administration
Clinical narrative: This spontaneous report was received from a pharmacist via Pfizer refers to a male patient of unknown age. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date, the patient was vaccinated with first dose of PNEUMOVAX 23 (lot number, expiration date, dose and route of administration were not reported) for prophylaxis. On an unknown date in 2017 (reported as 2 years ago), the patient did not receive the second dose of PNEUMOVAX 23, when the patient was supposed to get vaccinated.
Sex: M
Vaccine: PPV
Symptoms: Induration, Musculoskeletal pain
Clinical narrative: This spontaneous report was received from an unspecified reporter via company representative and concerns a male patient of unknown age. The patients concurrent conditions, pertinent medical history, concomitant therapies, drug reactions or allergies were not provided. On 19-FEB-2019, the patient was vaccinated with PNEUMOVAX 23 injection (lot #, expiry date, exact dose, route of administration and anatomical location were not provided) for prophylaxis. On an unknown date in February 2019, the patient experienced shoulder pain and hardness at shoulder near the injection site. The outcome of reported adverse events was unknown. The causality assessment was not provided.
Sex: F
Vaccine: VARZOS
Symptoms: Cerebrovascular accident
Clinical narrative: Information has been received regarding a case in litigation from a lawyer, a female patient of unknown age, and her spouse. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. In or around 2017, the patient was inoculated with the ZOSTAVAX (lot number, dosage and route of administration not provided) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). In approximately 2017 [reported as shortly after receiving ZOSTAVAX], the patient suffered a stroke. As a direct and proximate result of the ZOSTAVAX vaccine, the patient's symptoms have resulted in physical limitations not present prior to using ZOSTAVAX. The patient also experienced mental and emotional distress due to resulting physical limitations and the seriousness of the patient's condition. As a result of ZOSTAVAX, the patient sustained severe and permanent personal injuries. Further, as a tragic consequence, the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate consequence of ZOSTAVAX, the patient sustained serious personal injuries and related losses including, but not limited to, the following: Patient required and will continue to require healthcare and services; the patient incurred and will continue to incur medical and related expenses; and the patient suffered and will continue to suffer mental anguish, physical pain and suffering, diminished capacity for the enjoyment of life, a diminished quality of life, and other losses and damages. The outcome of the stroke was considered to be not recovered. Upon internal review, stroke was determined to be medically significant. Stroke was considered to be disabling. Additional information has been requested.
Age: 0.25
Sex: U
Vaccine: RV5, RV5
Symptoms: No adverse event, Product storage error
Clinical narrative: This spontaneous report as received from a medical assistant refers to a 3 month old infant patient of unknown gender. The patient's concurrent conditions, medical history, concomitant medications, drug reactions and allergies were not reported. On 05-OCT-2018, the patient was vaccinated with improperly stored dose of ROTATEQ 2 ml tube, orally (lot # N022015, expiry date: 10-MAR-2019) for prophylaxis. The vaccine was exposed to the temperature of 32.21 degree Fahrenheit (°F) (32F to 35 F) and time frame was 3.5 hours from 06-SEP-2018. Previous excursion was 50.37°F for 4.5 hours as recorded by a data logger. No adverse effect was reported. No product quality complaint was involved. This is one of the several reports received from the same reporter source. Sender's Comments: US-009507513-1809USA002868: Original Case: 1809USA002868; US-009507513-1902USA009324: Original Case: 1902USA009323; US-009507513-1902USA009323: Original Case: 1902USA009323; US-009507513-1902USA009326: Original Case: 1902USA009323.
Age: 0.25
Sex: U
Vaccine: RV5, RV5
Symptoms: No adverse event, Product storage error
Clinical narrative: This spontaneous report as received from a medical assistant refers to a 3 month old patient of unknown gender. The patient's concurrent conditions, medical history, concomitant medications, drug reactions and allergies were not reported. On 16-NOV-2018, the patient was vaccinated with improperly stored dose of ROTATEQ 2 ml tube, orally (lot # R007988, expiry date: 16-OCT-2019) for prophylaxis. The vaccine was exposed to the temperature of 32.21 degree Fahrenheit (°F) (32F to 35 F) and time frame was 3.5 hours from 06-SEP-2018. Previous excursion was 50.37 °F for 4.5 hours as recorded by a data logger. No adverse effect was reported. No product quality complaint was involved. This is one of the several reports received from the same reporter source.; Sender's Comments: US-009507513-1809USA002868: Original Case : 1809USA002868 US-009507513-1902USA009324: Original Case : 1902USA009323 US-009507513-1902USA009325: Original Case : 1902USA009323 US-009507513-1902USA009323: Original Case : 1902USA009323.
Age: 0.17
Sex: U
Vaccine: RV5
Symptoms: No adverse event, Product storage error
Clinical narrative: This spontaneous report as received from a medical assistant refers to a 9 week old patient of unknown gender. The patient's concurrent conditions, medical history, concomitant medications, drug reactions and allergies were not reported. On 16-NOV-2018, the patient was vaccinated with improperly stored dose of ROTATEQ 2 ml tube, orally (lot # R007988, expiry date: 16-OCT-2019) for prophylaxis. The vaccine was exposed to the temperature of 32.21 degree Fahrenheit (°F) (32F to 35 F) and time frame was 3.5 hours from 06-SEP-2018. Previous excursion was 50.37°F for 4.5 hours as recorded by a data logger. No adverse effect was reported. No product quality complaint was involved. This is one of the several reports received from the same reporter source. Sender's Comments: US-009507513-1809USA002868: Original Case: 1809USA002868; US-009507513-1902USA009324: Original Case: 1902USA009323; US-009507513-1902USA009325: Original Case: 1902USA009323; US-009507513-1902USA009323: Original Case: 1902USA009323.
Sex: F
Vaccine: VARZOS
Symptoms: Malaise, Rash generalised
Clinical narrative: This spontaneous case was received from a pharmacist via consumer (colleague) regarding his mother of unknown age. Her concurrent conditions, medical history, drug reactions/allergies and concomitant medications were unknown. On an unknown date (also reported as many years ago), the patient was vaccinated with ZOSTAVAX (strength, dose, dose number, unit, route, lot #, expiration date and anatomical location was not reported) for prophylaxis. On an unknown date, the patient experienced rash all over (rash generalized). The reporter stated that as per the consumer, the rash was not an outbreak of shingles but it was unknown how that determination was made. The reporter also stated that the patient was really sick post vaccination (malaise). It was also reported that it was unknown whether the patient sought medical attention and whether any treatment was provided to the patient. Lab diagnostics/studies were reported to be unknown. The event was called in at the time it occurred to the respective company but it was unknown when and which company. Outcome of rash generalized and malaise was unknown. Causality assessment of the events were not provided. No product quality complaint (PQC) was involved.
Age: 1.0
Sex: U
Vaccine: HEPA
Symptoms: No adverse event, Product storage error
Clinical narrative: This spontaneous report as received from a medical assistant refers to a 12 month old patient of unknown gender. The patient's concurrent conditions, medical history, concomitant medications, drug reactions and allergies were not reported. On 19-SEP-2018, the patient was vaccinated with improperly stored dose of VAQTA ped 0.5 ml vial (dose, frequency and route were not reported) (lot # R009953, expiry date: 12-JUN-2019) for prophylaxis. The vaccine was exposed to the temperature of 32.21 degree Fahrenheit (°F) (32F to 35 F) for 3.5 hours on 06-SEP-2018. Previous excursion was 50.37°F for 4.5 hours as recorded by a data logger. No adverse effect was reported. No product quality complaint was involved. This is one of the several reports received from the same reporter source. Sender's Comments: US-009507513-1809USA002868: Original Case: 1809USA002868; US-009507513-1902USA009324: Original Case: 1902USA009323; US-009507513-1902USA009325: Original Case: 1902USA009323; US-009507513-1902USA009326: Original Case: 1902USA009323.